Developer docs
API playgroundTry for free, no card

Search company profiles

SELLAS Life Sciences Group

Full company profile

uuid0003y6q

Namestring
SELLAS Life Sciences Group
Legal namestring
SELLAS Life Sciences Group, Inc.
Company typeenum
Public
Founded yearint
2003
Descriptiontext

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company headquartered at 7 Times Square, New York, focused on developing novel cancer therapeutics across hematologic malignancies and solid tumors. The company's pipeline is built on two core, in-licensed assets: galinpepimut-S (GPS), a multi-peptide cancer immunotherapeutic licensed globally from Memorial Sloan Kettering Cancer Center that targets the Wilms Tumor 1 (WT1) protein — ranked by the NCI as the top-priority cancer antigen — using AI-designed heteroclitic peptides to elicit CD4+ and CD8+ T-cell responses; and SLS009 (tambiciclib), a highly selective small-molecule CDK9 inhibitor licensed from GenFleet Therapeutics for development and commercialization worldwide outside Greater China, which downregulates MCL-1 and c-MYC to overcome venetoclax resistance in AML. GPS is in a pivotal Phase 3 REGAL trial in AML patients in second complete remission (78 of 80 survival events reached as of May 2026), with completed Phase 2 data also in MPM and multiple myeloma; SLS009 is in Phase 2 for relapsed/refractory and newly diagnosed AML, with a 46% ORR in combination with venetoclax/azacitidine and topline data expected Q4 2026.

SELLAS currently has no commercial products and no product revenue. Its economics rely on equity financings, warrant exercises, an at-the-market facility, and the potential future monetization of assets via partnership, licensing, or strategic transaction. The company operates with 51–100 employees, runs approximately 95 clinical trial sites across the US, Europe, and Asia, and maintains regional partnerships with 3D Medicines (Greater China rights for GPS and GPS+) and GenFleet Therapeutics (SLS009 Greater China and PTCL co-development). Recent signals — including change-of-control amendments to executive employment agreements and a 382% twelve-month stock return on M&A speculation — indicate the company is positioning for a potential strategic transaction ahead of the Phase 3 REGAL readout and the SLS009 Phase 2 readout.

Short descriptiontext

SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing novel cancer immunotherapeutics and a selective CDK9 inhibitor for hematologic malignancies and solid tumors, with lead assets GPS and SLS009 in Phase 3 and Phase 2 trials respectively for AML.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, WT1 targeting therapy, CDK9 inhibitor, acute myeloid leukemia treatment, clinical-stage biopharmaceutical
Industry3 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical-Stage Oncology Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1No current revenue
TypeLicensing Royalties
Description

SELLAS Life Sciences is a clinical-stage biopharmaceutical company with no commercialized products and no current revenue. The company is entirely focused on research and development of cancer therapeutics. All funding comes from equity financings, warrant exercises, and potential future licensing/partnership deals.

sellaslifesciences.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1GPS (Galinpepimut-S)
Description

WT1-targeting cancer immunotherapeutic agent targeting the Wilms tumor 1 protein, licensed from Memorial Sloan Kettering Cancer Center. Under development for AML, multiple myeloma, ovarian cancer, and malignant pleural mesothelioma.

sellaslifesciences.com
+1 more record
Core offering1 text field

SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing two main therapeutic candidates: galinpepimut-S (GPS), a multi-peptide cancer immunotherapeutic targeting the Wilms Tumor 1 (WT1) protein licensed from Memorial Sloan Kettering Cancer Center, and SLS009 (tambiciclib), a highly selective small molecule CDK9 inhibitor licensed from GenFleet Therapeutics. Both candidates are being advanced through clinical trials primarily for hematologic malignancies such as acute myeloid leukemia (AML).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 2 AML CR2 study: Median OS of 67.6 months with GPS maintenance vs. 5.4 months for best standard care (p<0.02)
+3 more records
Product overview1 text field

SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapies. The company's product portfolio centers on two clinical-stage therapeutic candidates: Galinpepimut-S (GPS), a WT1-targeting immunotherapeutic licensed from Memorial Sloan Kettering Cancer Center, and SLS009, a highly selective CDK9 inhibitor licensed from GenFleet Therapeutics. GPS is undergoing a pivotal Phase 3 REGAL trial for acute myeloid leukemia, while SLS009 is in Phase 2 development for AML. The company also holds rights to GPS+, a next-generation heptavalent immunotherapeutic (preclinical stage) for Greater China territory.

Product and service2 records
1Galinpepimut-S (GPS)
CategoryWT1 Cancer Immunotherapeutic
Description

Galinpepimut-S (GPS) is a WT1-targeting cancer immunotherapeutic containing four peptides (including AI-designed heteroclitic peptides) that elicit CD4+ and CD8+ T-cell immune responses against the Wilms Tumor 1 protein. It is in a pivotal Phase 3 REGAL trial for AML patients in second complete remission (CR2) who are ineligible for allogeneic stem cell transplant, and has completed Phase 2 trials in AML, ovarian cancer, malignant pleural mesothelioma, and multiple myeloma.

2SLS009 (tambiciclib)
CategorySelective CDK9 Inhibitor
Description

SLS009 (tambiciclib) is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor that decreases MCL-1 and c-MYC levels, leading to cancer cell apoptosis. In-licensed from GenFleet Therapeutics for development outside Greater China, SLS009 is being studied in a Phase 2 trial in newly diagnosed first-line AML (with topline data expected Q4 2026) and Phase 1b/II trials in relapsed/refractory AML (showing a 46% overall response rate in combination with venetoclax/azacitidine) and relapsed/refractory PTCL.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-03-01
Description

March 2022: Exclusive license agreement with GenFleet Therapeutics, a clinical-stage biotechnology company focused on oncology and immunology, for SLS009 (highly selective CDK9 inhibitor) across all therapeutic and diagnostic uses worldwide outside of the Greater China Region. SLS009 is SELLAS's second clinical-stage asset.

Strategic tierRegionalTypeTechnology or IntegrationAnnounced on2020-12-01
Description

December 2020: Exclusive license agreement with 3D Medicines Inc., a China-based biopharmaceutical company, for the development and commercialization of GPS and next-generation GPS+ across all therapeutic and diagnostic uses in Greater China territory (mainland China, Hong Kong, Macau, and Taiwan). SELLAS retains sole rights outside Greater China.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2014-09-01
Description

September 2014: SELLAS entered an exclusive global collaboration and license agreement with MSKCC for the development, marketing, and commercialization of MSKCC's proprietary WT1 cancer immunotherapy, galinpepimut-S (GPS). This is SELLAS's core technology platform and primary product candidate.

Strategic tierRegionalTypeStrategic or Co-development Partner
Description

Phase Ib/II study of SLS009 monotherapy in relapsed/refractory PTCL in China, sponsored and fully funded by GenFleet Therapeutics. Will enroll up to 95 patients across two stages.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing targeted radiotherapies for hematologic malignancies, particularly AML. Direct comparable as a small-cap oncology biotech with similar pipeline stage, AML focus, and reliance on capital markets for funding.

2MEI Pharma
TypeDirect peer
Description

Late-stage clinical oncology company focused on hematologic cancers with in-licensed and proprietary drug candidates. Direct comparable to SELLAS in scale, stage, oncology-only focus, and clinical development model targeting AML and related indications.

TypeBroad incumbent
Description

Global biopharmaceutical company commercializing venetoclax (Venclexta) for AML in combination with azacitidine. Broad incumbent competitor in the AML space where SELLAS's SLS009 is positioned to address venetoclax-resistant populations.

TypeDirect peer
Description

Clinical-stage specialty oncology company developing innovative treatments for hematologic malignancies and solid tumors. Direct comparable as a small-cap, clinical-stage oncology biotech with no commercial revenue, multiple in-licensed assets, and a similar investor profile and dilution trajectory.

5Bristol-Myers Squibb
TypeBroad incumbent
Description

Large pharmaceutical company with established AML franchise (azacitidine/Vidaza, cytarabine combinations) and broad oncology portfolio. Represents a likely strategic acquirer for SELLAS given overlap in AML and immunotherapy areas.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways. Comparable as an emerging clinical-stage oncology company with similar pipeline stage and capital markets dependency, though different mechanistic focus.

7Theseus Pharmaceuticals
TypeEmerging player
Description

Clinical-stage oncology company developing tyrosine kinase inhibitors for cancer treatment including hematologic malignancies. Comparable as a small-cap, AML-focused clinical-stage oncology company with similar pipeline stage.

8Syros Pharmaceuticals
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing treatments for hematologic malignancies through gene regulation. Comparable as a small-cap, clinical-stage biotech focused on hematologic cancers with similar regulatory and funding profile.

TypeDirect peer
Description

Clinical-stage biotechnology company developing precision therapies for genetically defined diseases including hematologic malignancies. Comparable as a small-cap, clinical-stage oncology company with multiple assets in development and similar financial profile.

TypeRegional player
Description

Shanghai-based clinical-stage biotechnology company focused on oncology and immunology, and SELLAS's licensor for SLS009. Regional peer operating in the same oncology space, holding Greater China rights to SLS009 and developing it independently there.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SELLAS Life Sciences Group

Clinical-Stage Oncology Biopharmaceuticalssellaslifesciences.com

SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing novel cancer immunotherapeutics and a selective CDK9 inhibitor for hematologic malignancies and solid tumors, with lead assets GPS and SLS009 in Phase 3 and Phase 2 trials respectively for AML.

What SELLAS Life Sciences Group does

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company headquartered at 7 Times Square, New York, focused on developing novel cancer therapeutics across hematologic malignancies and solid tumors. The company's pipeline is built on two core, in-licensed assets: galinpepimut-S (GPS), a multi-peptide cancer immunotherapeutic licensed globally from Memorial Sloan Kettering Cancer Center that targets the Wilms Tumor 1 (WT1) protein — ranked by the NCI as the top-priority cancer antigen — using AI-designed heteroclitic peptides to elicit CD4+ and CD8+ T-cell responses; and SLS009 (tambiciclib), a highly selective small-molecule CDK9 inhibitor licensed from GenFleet Therapeutics for development and commercialization worldwide outside Greater China, which downregulates MCL-1 and c-MYC to overcome venetoclax resistance in AML. GPS is in a pivotal Phase 3 REGAL trial in AML patients in second complete remission (78 of 80 survival events reached as of May 2026), with completed Phase 2 data also in MPM and multiple myeloma; SLS009 is in Phase 2 for relapsed/refractory and newly diagnosed AML, with a 46% ORR in combination with venetoclax/azacitidine and topline data expected Q4 2026.

SELLAS currently has no commercial products and no product revenue. Its economics rely on equity financings, warrant exercises, an at-the-market facility, and the potential future monetization of assets via partnership, licensing, or strategic transaction. The company operates with 51–100 employees, runs approximately 95 clinical trial sites across the US, Europe, and Asia, and maintains regional partnerships with 3D Medicines (Greater China rights for GPS and GPS+) and GenFleet Therapeutics (SLS009 Greater China and PTCL co-development). Recent signals — including change-of-control amendments to executive employment agreements and a 382% twelve-month stock return on M&A speculation — indicate the company is positioning for a potential strategic transaction ahead of the Phase 3 REGAL readout and the SLS009 Phase 2 readout.

SELLAS Life Sciences Group firmographics

Firmographics
Name
SELLAS Life Sciences Group
Legal name
SELLAS Life Sciences Group, Inc.
Website
https://sellaslifesciences.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
51–100 employees
Short description
SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing novel cancer immunotherapeutics and a selective CDK9 inhibitor for hematologic malignancies and solid tumors, with lead assets GPS and SLS009 in Phase 3 and Phase 2 trials respectively for AML.
Ownership category
akta.pro rank

SELLAS Life Sciences Group industry classification

Industry
Product category
Clinical-Stage Oncology Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals

Keywords

  • Cancer immunotherapy
  • WT1 targeting therapy
  • CDK9 inhibitor
  • Acute myeloid leukemia treatment
  • Clinical-stage biopharmaceutical

Where SELLAS Life Sciences Group is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

SELLAS Life Sciences Group business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. No current revenue: SELLAS Life Sciences is a clinical-stage biopharmaceutical company with no commercialized products and no current revenue. The company is entirely focused on research and development of cancer therapeutics. All funding comes from equity financings, warrant exercises, and potential future licensing/partnership deals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

SELLAS Life Sciences Group product offering

Product offering

Core offering

SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing two main therapeutic candidates: galinpepimut-S (GPS), a multi-peptide cancer immunotherapeutic targeting the Wilms Tumor 1 (WT1) protein licensed from Memorial Sloan Kettering Cancer Center, and SLS009 (tambiciclib), a highly selective small molecule CDK9 inhibitor licensed from GenFleet Therapeutics. Both candidates are being advanced through clinical trials primarily for hematologic malignancies such as acute myeloid leukemia (AML).

Product overview

SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapies. The company's product portfolio centers on two clinical-stage therapeutic candidates: Galinpepimut-S (GPS), a WT1-targeting immunotherapeutic licensed from Memorial Sloan Kettering Cancer Center, and SLS009, a highly selective CDK9 inhibitor licensed from GenFleet Therapeutics. GPS is undergoing a pivotal Phase 3 REGAL trial for acute myeloid leukemia, while SLS009 is in Phase 2 development for AML. The company also holds rights to GPS+, a next-generation heptavalent immunotherapeutic (preclinical stage) for Greater China territory.

Differentiator

Problem solved

Functional benefit

Brands

  • GPS (Galinpepimut-S): WT1-targeting cancer immunotherapeutic agent targeting the Wilms tumor 1 protein, licensed from Memorial Sloan Kettering Cancer Center. Under development for AML, multiple myeloma, ovarian cancer, and malignant pleural mesothelioma.
  • SLS009

Products and services

  • Galinpepimut-S (GPS) Galinpepimut-S (GPS) is a WT1-targeting cancer immunotherapeutic containing four peptides (including AI-designed heteroclitic peptides) that elicit CD4+ and CD8+ T-cell immune responses against the Wilms Tumor 1 protein. It is in a pivotal Phase 3 REGAL trial for AML patients in second complete remission (CR2) who are ineligible for allogeneic stem cell transplant, and has completed Phase 2 trials in AML, ovarian cancer, malignant pleural mesothelioma, and multiple myeloma.
  • SLS009 (tambiciclib) SLS009 (tambiciclib) is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor that decreases MCL-1 and c-MYC levels, leading to cancer cell apoptosis. In-licensed from GenFleet Therapeutics for development outside Greater China, SLS009 is being studied in a Phase 2 trial in newly diagnosed first-line AML (with topline data expected Q4 2026) and Phase 1b/II trials in relapsed/refractory AML (showing a 46% overall response rate in combination with venetoclax/azacitidine) and relapsed/refractory PTCL.

Quantifiable outcome

  • Phase 2 AML CR2 study: Median OS of 67.6 months with GPS maintenance vs. 5.4 months for best standard care (p<0.02)
  • +3 more outcomes

Companies that use SELLAS Life Sciences Group

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

SELLAS Life Sciences Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

SELLAS Life Sciences Group partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and regional.

  • GenFleet Therapeutics (Shanghai) Inc.coreTechnology or Integration · 1 March 2022March 2022: Exclusive license agreement with GenFleet Therapeutics, a clinical-stage biotechnology company focused on oncology and immunology, for SLS009 (highly selective CDK9 inhibitor) across all therapeutic and diagnostic uses worldwide outside of the Greater China Region. SLS009 is SELLAS's second clinical-stage asset.
  • 3D Medicines Inc.regionalTechnology or Integration · 1 December 2020December 2020: Exclusive license agreement with 3D Medicines Inc., a China-based biopharmaceutical company, for the development and commercialization of GPS and next-generation GPS+ across all therapeutic and diagnostic uses in Greater China territory (mainland China, Hong Kong, Macau, and Taiwan). SELLAS retains sole rights outside Greater China.
  • Memorial Sloan Kettering Cancer Center (MSKCC)coreTechnology or Integration · 1 September 2014September 2014: SELLAS entered an exclusive global collaboration and license agreement with MSKCC for the development, marketing, and commercialization of MSKCC's proprietary WT1 cancer immunotherapy, galinpepimut-S (GPS). This is SELLAS's core technology platform and primary product candidate.
  • GenFleet Therapeutics (NCT05934513)regionalStrategic or Co-development PartnerPhase Ib/II study of SLS009 monotherapy in relapsed/refractory PTCL in China, sponsored and fully funded by GenFleet Therapeutics. Will enroll up to 95 patients across two stages.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

SELLAS Life Sciences Group competitors and assessment

Company assessment

Direct peers

  • Actinium Pharmaceuticals: Clinical-stage biopharmaceutical company developing targeted radiotherapies for hematologic malignancies, particularly AML. Direct comparable as a small-cap oncology biotech with similar pipeline stage, AML focus, and reliance on capital markets for funding.
  • MEI Pharma: Late-stage clinical oncology company focused on hematologic cancers with in-licensed and proprietary drug candidates. Direct comparable to SELLAS in scale, stage, oncology-only focus, and clinical development model targeting AML and related indications.
  • Karyopharm Therapeutics: Clinical-stage specialty oncology company developing innovative treatments for hematologic malignancies and solid tumors. Direct comparable as a small-cap, clinical-stage oncology biotech with no commercial revenue, multiple in-licensed assets, and a similar investor profile and dilution trajectory.
  • Syros Pharmaceuticals: Clinical-stage biopharmaceutical company developing treatments for hematologic malignancies through gene regulation. Comparable as a small-cap, clinical-stage biotech focused on hematologic cancers with similar regulatory and funding profile.
  • Cogent Biosciences: Clinical-stage biotechnology company developing precision therapies for genetically defined diseases including hematologic malignancies. Comparable as a small-cap, clinical-stage oncology company with multiple assets in development and similar financial profile.

Broad incumbents

  • AbbVie: Global biopharmaceutical company commercializing venetoclax (Venclexta) for AML in combination with azacitidine. Broad incumbent competitor in the AML space where SELLAS's SLS009 is positioned to address venetoclax-resistant populations.
  • Bristol-Myers Squibb: Large pharmaceutical company with established AML franchise (azacitidine/Vidaza, cytarabine combinations) and broad oncology portfolio. Represents a likely strategic acquirer for SELLAS given overlap in AML and immunotherapy areas.

Emerging players

  • Aprea Therapeutics: Clinical-stage biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways. Comparable as an emerging clinical-stage oncology company with similar pipeline stage and capital markets dependency, though different mechanistic focus.
  • Theseus Pharmaceuticals: Clinical-stage oncology company developing tyrosine kinase inhibitors for cancer treatment including hematologic malignancies. Comparable as a small-cap, AML-focused clinical-stage oncology company with similar pipeline stage.

Regional players

  • GenFleet Therapeutics: Shanghai-based clinical-stage biotechnology company focused on oncology and immunology, and SELLAS's licensor for SLS009. Regional peer operating in the same oncology space, holding Greater China rights to SLS009 and developing it independently there.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

SELLAS Life Sciences Group social profiles

Digital presence

SELLAS Life Sciences Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SELLAS Life Sciences Group leadership team

Management profile

Number of profiles

Profiles5 records

SELLAS Life Sciences Group funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SELLAS Life Sciences Group M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SELLAS Life Sciences Group

What does SELLAS Life Sciences Group do?

SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing two main therapeutic candidates: galinpepimut-S (GPS), a multi-peptide cancer immunotherapeutic targeting the Wilms Tumor 1 (WT1) protein licensed from Memorial Sloan Kettering Cancer Center, and SLS009 (tambiciclib), a highly selective small molecule CDK9 inhibitor licensed from GenFleet Therapeutics. Both candidates are being advanced through clinical trials primarily for hematologic malignancies such as acute myeloid leukemia (AML).

Is SELLAS Life Sciences Group a public or private company?

SELLAS Life Sciences Group is a public company. It is classified as public and is currently operating.

When was SELLAS Life Sciences Group founded?

SELLAS Life Sciences Group was founded in 2003. It employs 51 to 100 people.

Where is SELLAS Life Sciences Group based?

SELLAS Life Sciences Group is headquartered in New York, United States, in the North America region.

How does SELLAS Life Sciences Group make money?

One revenue line is on record: no current revenue.

Who are SELLAS Life Sciences Group's main competitors?

Direct peers on record are Actinium Pharmaceuticals, MEI Pharma, Karyopharm Therapeutics, Syros Pharmaceuticals and Cogent Biosciences. Broad incumbents are AbbVie and Bristol-Myers Squibb. Emerging players are Aprea Therapeutics and Theseus Pharmaceuticals. GenFleet Therapeutics is listed as a regional player.

Does SELLAS Life Sciences Group have an API?

No public API is recorded for SELLAS Life Sciences Group.

What industry is SELLAS Life Sciences Group in?

SELLAS Life Sciences Group's product category is Clinical-Stage Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewWhy SELLAS Life Sciences Group shares are falling todaySELLAS Life Sciences Group shares fell 19.1% after the company priced an underwritten public offering of 11,538,462 shares at $13.00 each, with gross proceeds expected at $150 million. The offering closes November 20, 2026, and the stock traded at $14.80, down 17.7% from the previous close.MarketWatchSellas Life Sciences Shares Sink After Pricing Public OfferingSellas Life Sciences Group priced a $150 million public offering, selling over 11.5 million shares at $13 each. Shares fell 22% to $13.98 in premarket trading, though they have more than quadrupled year to date. The offering is expected to close on Friday.The future of tradingSellas Life Sciences Announces Pricing Of $150.0 Million Underwritten Public OfferingSellas Life Sciences Group priced a $150 million underwritten public offering of 11,538,462 shares at $13 per share. The offering is fully underwritten, with no proceeds from the offering.TradingViewSELLAS Life Sciences Group, Inc. (SLS) Prices $150M Share OfferingSELLAS Life Sciences Group priced 11,538,462 shares at $13.00 each, expecting gross proceeds of $150M before fees. The offering closes on November 20, 2026, subject to customary conditions, with a 30-day option for up to 1,730,769 additional shares.Simply Wall StWhat Does SELLAS Life Sciences Group (SLS) Phase 3 AML Success Change Now?SELLAS Life Sciences Group reported that its Phase 3 REGAL trial of galinpepimut S in AML met the primary overall survival endpoint. The trial showed a median overall survival of 24.0 months versus 14.7 months for best available treatment, a 41% reduction in death risk, and no new safety issues. The company plans to submit a Biologics License Application to the FDA for GPS in AML, seeking accelerated review.Seeking AlphaSELLAS Life Sciences Group, Inc. (SLS) Discusses Positive Phase III REGAL Trial Results for Galinpepimut-S in Acute Myeloid Leukemia Prepared Remarks TranscriptSELLAS Life Sciences announced positive top-line results from its Phase III REGAL trial of galinpepimut-S in acute myeloid leukemia. The company's CEO called the results a historic milestone after 15 years of development. The call included forward-looking statements subject to risks.Seeking AlphaSELLAS Life Sciences launches $150M public offering of its sharesSELLAS Life Sciences Group commenced an underwritten public offering of $150 million in common stock. The company granted underwriters a 30-day option to purchase up to an additional $22.5 million. The stock is trading at $19.15, up 156.36% from the previous close.TradingViewSELLAS Life Sciences Group (SLS) Proposes $150.0M Share OfferingSELLAS Life Sciences Group proposed an underwritten public offering of $150 million in common stock, with a 30-day option for up to $22.5 million more. All shares will be sold by SELLAS, and completion and terms are subject to market conditions.